The companies said early trials showed the vaccine produced an “insufficient” immune response in people over 60 because it didn’t contain enough of the material that triggers the production of disease-fighting antibodies. 



from Section Page News - Modern Healthcare https://ift.tt/379CiLK
via IFTTT